Nanoemulsions: colloidal topical delivery systems for antiacne agents- A Mini-Review

Document Type: Mini Review Paper


1 Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Medical Biomaterials Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran


One of the common chronic inflammatory skin diseases is Acne Vulgaris that affects up to 80% of a teen-age population. The progress of acne lesions is due to colonization of Propionibacterium acnes (P .acnes) in hair follicles. Treatment of acne includes topical or systemic therapy or combination therapy, with a tendency to perform topical therapy in mild to moderate acne. Nanoemulsions, small oil droplet less than 200nm, which have been stabilized by surfactant(s) and/or co-surfactant in water, could be effective carriers for topical delivery of anti-acne agents. Interesting properties of nanoemulsions such as the improved efficacy of the drug, ease of production, ability to be used in various formulations and ability to load lipophilic drugs could make it an ideal carrier for this purpose. This review highlights applications of nanoemulsions for topical therapy of acne. 

Graphical Abstract

Nanoemulsions: colloidal topical delivery systems for antiacne agents- A Mini-Review



Acne vulgaris is a common chronic inflammatory disease which develops in any age, with a greater prevalence in adults. Acne is not life-threatening but can affect self-esteem in patients [1]. Clinical features of the disease include excessive oil production by sebaceous glands in the skin, non-inflammatory lesions (open and closed comedones), inflammatory lesions (papules and pustules), nodules and cysts as well as different degrees of dermal scarring. Anatomical distribution of acne lesions are in the face, neck, upper chest, shoulders and back [2].

Acne is usually classified based on its severity as mild, moderate, or severe. Mild acne is characterized by the presence of minor pimples, whiteheads, and blackheads comedones, without inflammation. Patients with moderate acne have greater blackheads, papules and pustules, with slight inflammation. Characteristics of severe acne include severe papules/ pustules comedones and cystic nodules that are often painful and can leave a scar on the skin [3].

In this review, pathogenesis of acne as well as conventional formulations for acne treatment are briefly explained. We then will focus on nanoemulsions as potential colloidal systems for delivering anti-acne agents.



A multifactorial mechanism is involved in the pathogenesis of acne (see the schematic shown in Figure 1) [4].

Various factors including the presence of hormones, sebum, bacteria in the pilosebaceous units of dermis and keratinization of follicles have been associated in the literature with acne. An increase in sebum production is probably the main factor for the disease. Sebum provides a substrate for growth of P. acnes as a part of the bacterial flora of normal skin that is located within the follicles and needs the sebaceous constituent for nourishment. Hyperkeratinization of follicles which blocks flow of sebum in the pilosebaceous canal is another cause of acne. Further to a colonization of Staphylococcus epidermidis and P. acnes in pilosebaceous units, a cascade of events leads to inflammatory and non-inflammatory lesions. Such events include release of chemotactic factors, phagocytosis of bacteria by neutrophils and rupture of the follicular wall as a result of hydrolytic enzymes of neutrophils [5, 6]. A brief mechanism of acne pathogenesis is shown in Figure 2.



Main treatment in mild to moderate acne is topical therapy. In severe conditions of acne, topical therapy may also be used as additional support for systemic therapy [6]. Topical medicines which are commonly used are retinoids, antibiotics, and herbal agents and are commercially available in the dosage form of cream, gel as summarized in Table 1. Topical treatments only work where applied and some of them cause cutaneous irritation that can be minimized by using lower concentration formulations [5].

Systemic therapy is reserved for moderate and severe acne. Drugs that are used for systemic applications are isotretinoin, systemic antibiotics (e.g. tetracycline, doxycycline, minocycline, erythromycin, and azithromycin) and hormonal therapy [13]. Also, the combination of more than a single topical or systemic drug is a common approach in complicated cases as this method can target several pathogenic factors [14]. Several studies have shown combination therapy as an efficient therapy compared with monotherapy for acne treatment [15-17].

When comparing with systemic therapy, topical application of drugs shows substantially lesser adverse effects. For example, the only concern when using a topical form of retinoids is their tolerability and cutaneous irritation. Also, there is no important concern for topical antibiotics. While when taking orally, many side effects are expected from oral retinoids (isotretinoin) such as cheilitis, dry skin, nose bleeds, secondary infection, temporary worsening of lesions, photo sensitivity, and increased serum lipids. Antibiotic resistance is a concern in the systemic use of antibiotics [5, 8, 18, 19]. However, topical anti-acne drugs are less effective due to low penetration. To deal with this problem, patients should use the medicine for a long time that decreases patient compliance. Additionally, this may increase the risk of bacterial resistance [20]. Such problems indicate the necessity for developing novel topical formulations with improved efficacy.


The main site of disease in acne is follicular recesses of the skin, so, any applied antiacne agent must accumulate in follicular recesses in reasonable concentrations to be effective. Ease of use, production cost as well as safety and efficacy of formulations are also challenges ahead of a formulator.

Nanostructures provide many advantages for drug delivery systems. Improving efficacy of the active ingredient, controlling drug release profile and biological life-time as well as delivering multiple agents in a single preparation are some gains when “nano” is employed. In recent years, several reports have used various nanoparticles for delivering a drug in the treatment of acne [21-28]. In recent years, there has been a growing interest in the use of nanoemulsions as colloidal drug carriers for treatment of acne. For instance, in a research, extent and kinetics of drug deposition of tea tree oil through the follicular route were investigated in different formulations. The work demonstrated that microemulsion and liposomal formulations were more efficient for the delivery of tea tree oil [29].

Nanoemulsions are emulsions with a diameter less than 200nm. They are prepared using high energy emulsification methods (e.g. ultrasonication, microfluidizers and high-pressure homogenizers) or low energy emulsification ones (e.g. phase inversion and solvent displacement [30-38]. These nanocarriers offer advantages of transparency, low viscosity, thermodynamic stability, ease of preparation, a high surface area that make them effective transdermal and topical drug delivery systems. Also, compared with other nanocarriers, they provide some substantial advantages including low skin irritation, high permeation ability, and high drug-loading capacity for topical treatment [39]. Nanoemulsions have been formulated in different topical dosage forms such as foams, cream, gels, liquids and sprays [40, 41]. Some nanoemulsion-based products have been patented for skincare products [42-45].

Several mechanisms participate in improving drug penetration in topical delivery of nanoemulsions containing anti-acne drugs. The Small size of nanoemulsion droplets can increase drug transportation through hair follicles as the main target for P.acnes colonization and oil production by Sebaceous glands [46]. Furthermore, many of nanoemulsion excipients act as permeation enhancers in topical applications. Due to hydrophobic characteristics of skin, the oil phase of the nanoemulsion having hydrophobic properties can improve permeation of active ingredients [47]. Surfactants are also well known as penetration enhancers in the skin. They have potential to solubilize lipids within stratum corneum (SC) as the main barrier for topical absorption of drugs [48]. Penetration of the surfactant molecules into the lipid lamellae of the SC is strongly dependent on the partitioning behavior and solubility of surfactant [49]. Co-surfactants also can influence the transport behavior of the drug in the skin. For example, ethanol can increase lipophilic transport from SC through the formation of pores in SC [50, 51]. Also, since the hydrated skin is generally more permeable, water which is found in nanoemulsions is perhaps an ideal enhancer [52].

Table 2 lists the antiacne agents which have been formulated in nanoemulsions. Nanoemulsions also offer a great potential for boosting bioavailability of drugs, especially lipophilic drugs. Efficient transdermal drug delivery happens particularly with positively charged nanoemulsions [53].

Roy et al. reported a novel nanoemulsion with Soybean oil as oil phase loaded with clindamycin phosphate and adapalene. The preparation exhibited good therapeutic efficacy and improved permeability. A randomized clinical trial in Indian patients with the topical gel of this nanoemulsion showed better tolerance and efficacy than the conventional formulation for the treatment of acne vulgaris [54, 60]. In another study, nanoemulsion was prepared using isopropyl myristate which showed increased in-vitro epidermal permeation of dapsone while n-methyl-pyrrolidone as the oil phase provided a greater solubilization of dapsone, and increased release rate of the drug [55]. Nanoemulsions of lemongrass oil (no chemical agent) and oleic acid loaded with nadifloxacin also showed improved zone inhabitation properties against P. acnes as compared to clindamaycin [56, 57]. In another study, clindamycin loaded in olive oil nanoemulsion showed good physicochemical properties as the anti-acne carrier [58]. In study of Miastkowska et al. release kinetic of isotretinoin from coconut oil nanoemulsions was investigated. A zero order kinetic model was suggested for the nano-formulation which could be used as controlled drug release carrier for acne treatment [59].



Selection of appropriate components is an important step in the preparation of nanoemulsions. A nanoemulsion typically contains oil, surfactant, co-surfactant and water. These ingredients should be chosen properly to maximize the efficacy of the product.



The oil is probably the most important excipient in a nanoemulsion, because it is the main part of a nanoemulsion in solubilizing lipophilic drugs. As the majority of antiacne drugs possess high oil solubility, nanoemulsions could be suitable carriers for encapsulating them. Different types of oil have been employed in antiacne nanoemulsions. Length of fatty acids chain in the molecular structure of the oil is a main factor determining the stability of nanoemulsions. Nanoemulsions with short chain oil often have low viscosity, while oils with long chain fatty acids produce stable nanoemulsions with larger particle size [61].

Although solubility of the active ingredient in the oil phase is an important criterion in the selection of oil, in some cases synergistic effects of oil phase with the active ingredient for the intended application becomes very important too [62]. For example, essential oils of eucalyptus and tea tree are being traditionally employed in the treatment of acne [63]. Nanoemulsions of such oils may be used as a combination therapy when the oil is both an active ingredient and a carrier for a second drug.



Surfactants are amphiphilic molecules that consist of a non-polar hydrophobic portion which is attached to a hydrophilic portion. The hydrophobic part interacts readily with oil but is insoluble in water, while the hydrophilic part locates next to the water phase of the system [64]. Surfactants are usually classified as anionic, cationic and non-ionic. Non-ionic surfactants are less toxic than ionic ones. Examples of non-ionic surfactants include Tween, labrasol and Cremophor. Selection of an appropriate surfactant which efficiently emulsifies the oil is the most important factor in determining the stability of the product. HLB (hydrophilic lipophilic balance) value has been proven to be very useful in choosing the best type of surfactant for intended oil [64, 65].



Typically, short chain alcohols like ethanol and propylene glycol, are used as co-surfactants for decreasing interfacial tension and modifying fluidity of the interfacial layer. Co-surfactants also decrease viscosity and increase the stability of nanoemulsions. Additionally, they may help to dissolve hydrophilic surfactants or hydrophobic drugs in the oil phase [50, 66].



Although significant growth has been made in the treatment of acne, optimal treatment strategy can offer a promising potential for quick improvement with minimum adverse effects. Many topical and systemic treatments are available for treatment of acne. Nanoemulsions as nano-sized emulsions in carrying drugs have potential in topical anti-acne therapy. They offer better options in topical acne treatment due to enhancing penetration of the active ingredient(s). The correct selection of nanoemulsion components could enhance the efficiency of topical preparation. A good combination of an active agent with an appropriate oil would even result in a better effect.

1.Nguyen CM, Koo J, Cordoro KM. Psychodermatologic Effects of Atopic Dermatitis and Acne: A Review on Self‐Esteem and Identity. Pediatr Dermatol. 2016;33(2):129-35.

2.Shalita AR. Acne: clinical presentations. Clin Dermatol. 2004;22(5):385-6.

3.Jacob CI, Dover JS, Kaminer MS. Acne scarring: a classification system and review of treatment options. J Am Acad Dermatol. 2001;45(1):109-17.

4.Canavan TN, Chen E, Elewski BE. Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review. Dermatol Ther. 2016;6(4):555-78.

5.Williams HC, Dellavalle RP, Garner S. Acne vulgaris. The Lancet. 2012;379(9813):361-72.

6.Garg T. Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol. 2016;44(1):98-105.

7.Thielitz A, Abdel‐Naser MB, Fluhr JW, Zouboulis CC, Gollnick H. Topical retinoids in acne–an evidence‐based overview. J Dtsch Dermatol. 2008;6(12):1023-31.

8.Gallo RL, Nakatsuji T. Microbial symbiosis with the innate immune defense system of the skin. J Invest Dermatol. 2011;131(10):1974-80.

9.Lazic Mosler E, Leitner C, Gouda MA, Carter B, Layton AM, KhalafAllah MT. Topical antibiotics for acne. Cochrane Libr. 2016.

10.Lalla J, Nandedkar S, Paranjape M, Talreja N. Clinical trials of ayurvedic formulations in the treatment of acne vulgaris. J Ethnopharmacol. 2001;78(1):99-102.

11.Griffiths G, Trueman L, Crowther T, Thomas B, Smith B. Onions—a global benefit to health. Phytother Res. 2002;16(7):603-15.

12.Malhi HK, Tu J, Riley TV, Kumarasinghe SP, Hammer KA. Tea tree oil gel for mild to moderate acne; a 12 week uncontrolled, open‐label phase II pilot study. Australas J Dermatol. 2016.

13.Garshick MK, Kimball A, Drake L. Systemic Therapies for Acne.  Acneiform Eruptions in Dermatology: Springer; 2014. p. 27-34.

14.Simonart T. Newer approaches to the treatment of acne vulgaris. Am J Clin Dermatol. 2012;13(6):357-64.

15.Ricci F, Masini F, Fossati B, Frascione P, De Waure C, Capizzi R, et al. Combination therapy with hydrogen peroxide (4%), salicylic acid (0.5%) and D-panthenol (4%): efficacy and skyn tolerability in common acne vulgaris during sun exposure period. Eur Rev Med Pharmacol Sci. 2016;20(2):232-6.

16.Akarsu S, Fetil E, Yücel F, Gül E, Güneş AT. Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. J Dermatol. 2012;39(5):433-8.

17.Seidler EM, Kimball AB. Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. J Am Acad Dermatol. 2010;63(1):52-62.

18.Yentzer BA, McClain RW, Feldman SR. Do topical retinoids cause acne to" flare"? J Drugs Dermatol. 2009;8(9):799-801.

19.Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol. 2010;51(4):248-53.

20.Gollnick HP, Krautheim A. Topical treatment in acne: current status and future aspects. Dermatology. 2003;206(1):29-36.

21.Aytekin M, Gursoy RN, Ide S, Soylu EH, Hekimoglu S. Formulation and characterization of liquid crystal systems containing azelaic acid for topical delivery. Drug Dev Ind Pharm. 2013;39(2):228-39.

22.Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345(1):163-71.

23.Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363(1):132-8.

24.Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 2007;328(2):191-5.

25.Münster U, NakamuraNachname C, Haberland A, Jores K, Mehnert W, Rummel S, et al. RU 58841-myristate–prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie. 2005;60(1):8-12.

26.Štecová J, Mehnert W, Blaschke T, Kleuser B, Sivaramakrishnan R, Zouboulis CC, et al. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res. 2007;24(5):991-1000.

27.Layegh P, Mosallaei N, Bagheri D, Jaafari MR, Golmohammadzadeh S. The efficacy of isotretinoin-loaded solid lipid nanoparticles in comparison to Isotrex® on acne treatment. Nanomed J. 2013;1(1):38-47.

28.Domínguez-Delgado CL, Rodríguez-Cruz IM, Escobar-Chávez JJ, Calderón-Lojero IO, Quintanar-Guerrero D, Ganem A. Preparation and characterization of triclosan nanoparticles intended to be used for the treatment of acne. Eur J Pharm Biopharm. 2011;79(1):102-7.

29.Biju S, Ahuja A, Khar RK. Tea tree oil concentration in follicular casts after topical delivery: Determination by high‐performance thin layer chromatography using a perfused bovine udder model. J Pharm Sci. 2005;94(2):240-5.

30.Maali A, Mosavian MH. Preparation and application of nanoemulsions in the last decade (2000–2010). J DISPER SCI TECHNOL. 2013;34(1):92-105.

31.Lovelyn C, Attama AA. Current state of nanoemulsions in drug delivery. J Biomater Nanobiotechnol. 2011;2(05):626.

32.McClements DJ, Rao J. Food-grade nanoemulsions: formulation, fabrication, properties, performance, biological fate, and potential toxicity. Crit Rev Food Sci Nutr. 2011;51(4):285-330.

33.Qian C, McClements DJ. Formation of nanoemulsions stabilized by model food-grade emulsifiers using high-pressure homogenization: factors affecting particle size. Food Hydrocoll. 2011;25(5):1000-8.

34.Esmaeili F, Rajabnejhad S, Partoazar AR, Mehr SE, Faridi-Majidi R, Sahebgharani M, et al. Anti-inflammatory effects of eugenol nanoemulsion as a topical delivery system. Pharm Dev Technol. 2016;21(7):887-93.

35.Khani S, Keyhanfar F, Amani A. Design and evaluation of oral nanoemulsion drug delivery system of mebudipine. Drug Deliv. 2016;23(6):2035-43.

36.Amani A, York P, Chrystyn H, Clark BJ, Do DQ. Determination of factors controlling the particle size in nanoemulsions using Artificial Neural Networks. Eur J Pharm Sci. 2008;35(1):42-51.

37.Amani A, York P, Chrystyn H, Clark BJ. Factors affecting the stability of nanoemulsions—use of artificial neural networks. Pharm Res. 2010;27(1):37.

38.Amani A, York P, Chrystyn H, Clark BJ. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. Aaps Pharmscitech. 2010;11(3):1147-51.


40.Sharma S, Sarangdevot K. Nanoemulsions for cosmetics. IJARPB. 2012;1(3):408-15.

41.Sonneville-Aubrun O, Simonnet J-T, L'alloret F. Nanoemulsions: a new vehicle for skincare products. Adv Colloid Interface Sci. 2004;108:145-9.

42.Simonnet J-T, Sonneville O, Legret S, inventors; Google Patents, assignee. Nanoemulsion based on oxyethylenated or non-oxyethylenated sorbitan fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields2002.

43.Simonnet J-T, Sonneville O, Legret S, inventors; Google Patents, assignee. Nanoemulsion based on ethylene oxide and propylene oxide block copolymers and its uses in the cosmetics, dermatological and/or ophthalmological fields2002.

44.Simonnet J-T, Sonneville O, Legret S, inventors; Google Patents, assignee. Nanoemulsion based on sugar fatty esters or on sugar fatty ethers and its uses in the cosmetics, dermatological and/or ophthalmological fields2004.

45.Ribier A, Simonnet J-T, Legret S, inventors; Google Patents, assignee. Transparent nanoemulsion less than 100 nm based on fluid non-ionic amphiphilic lipids and use in cosmetic or in dermopharmaceuticals1998.

46.Denet A-R, Vanbever R, Préat V. Skin electroporation for transdermal and topical delivery. Adv Drug Deliv Rev. 2004;56(5):659-74.

47.Hoeller S, Sperger A, Valenta C. Lecithin based nanoemulsions: a comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. Int J Pharm. 2009;370(1):181-6.

48.POTTS RO, MAK VH, GUY RH. Strategies to enhance permeability via stratum corneum lipid pathways2016. 173 p.

49.Som I, Bhatia K, Yasir M. Status of surfactants as penetration enhancers in transdermal drug delivery. J Pharm Bioall Sci. 2012;4(1):2.

50.Ghanem A-H, Mahmoud H, Rohr UD, Borsadia S, Liu P, Fox JL, et al. The effects of ethanol on the transport of β-estradiol and other permeants in hairless mouse skin. II. A new quantitative approach. J Control Release. 1987;6(1):75-83.

51.Lane ME. Skin penetration enhancers. Int J Pharm. 2013;447(1):12-21.

52.Gupta RR, Jain SK, Varshney M. AOT water-in-oil microemulsions as a penetration enhancer in transdermal drug delivery of 5-fluorouracil. Colloids Surf B Biointerfaces. 2005;41(1):25-32.

53.Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 1). Trop J Pharm Res. 2013;12(2):255-64.

54.Roy SB, Kothari JS, Sheikh S, Pancholi JS, Patel JD, Mittal R, inventors; Google Patents, assignee. Pharmaceutical compositions of anti-acne agents2011. Almeida Borges VR, Simon A, Sena ARC, Cabral LM, de Sousa VP. Nanoemulsion containing dapsone for topical administration: a study of in vitro release and epidermal permeation. Int J Nanomedicine. 2013;8:535.

56.Faiyazuddin M, Baboota S, Ali J, Ahuja A, Ahmad S. Characterization and in vitro bioactive studies of lemongrass oil phytonanoemulsion system in the treatment of acne vulgaris. Int J Essent Oil Ther. 2009;3(1):13-21.

57.Kumar A, Agarwal S, Ahuja A, Ali J, Choudhry R, Baboot S. Preparation, characterization, and in vitro antimicrobial assessment of nanocarrier based formulation of nadifloxacin for acne treatment. Pharmazie. 2011;66(2):111-4.

58.Jiyauddin K, Fadli A, Wei J, Jawad A, Samer A, Kaleemullah M, et al. FORMULATION OF CLINDAMYCIN NANO-EMULSION. Int J Pharm Sci Res. 2015;6(5):1845.

59.Miastkowska M, Sikora E, Ogonowski J, Zielina M, Łudzik A. The kinetic study of isotretinoin release from nanoemulsion. Colloids Surf A Physicochem Eng Asp. 2016;510:63-8.

60.Prasad S, Mukhopadhyay A, Kubavat A, Kelkar A, Modi A, Swarnkar B, et al. Efficacy and safety of a nano-emulsion gel formulation of adapalene 0.1% and clindamycin 1% combination in acne vulgaris: a randomized, open label, active-controlled, multicentric, phase IV clinical trial. Indian J Dermatol Venereol Leprol. 2012;78(4):459.

61.Wooster TJ, Golding M, Sanguansri P. Impact of oil type on nanoemulsion formation and Ostwald ripening stability. Langmuir. 2008;24(22):12758-65.

62.Chaudhary M, Naithani V, inventors; Google Patents, assignee. Topical herbal formulation for treatment of acne and skin disorders2012.

63.Stevensen CJ. Aromatherapy in dermatology. Clin Dermatol. 1998;16(6):689-94.

64.Mandal A, Bera A. Surfactant stabilized nanoemulsion: characterization and application in enhanced oil recovery. WASET. 2012;6(7):537-42.

65.Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm. 2004;280(1):241-51.